WHO Meeting of Final Review of the RSV Surveillance Pilot Based on the Global Influenza Surveillance and Response System

Bangkok, Thailand 23 to 25 October 2018



WHO Reference number: WHO/WHE/IHM/2019.12

#### © World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO;

https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for noncommercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation**. WHO meeting of final review of the RSV surveillance pilot based on the global influenza surveillance and response system, Bangkok, Thailand, 23-25 October 2018. Geneva: World Health Organization; 2019 (WHO reference number WHO/WHE/IHM/2019/12). Licence: <u>CC BY-NC-SA 3.0 IGO</u>.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <u>http://apps.who.int/iris</u>. **Sales, rights and licensing.** To purchase WHO publications, see

<u>http://apps.who.int/bookorders</u>. To submit requests for commercial use and queries on rights and licensing, see <u>http://www.who.int/about/licensing</u>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication contains the report of the WHO Meeting of Final Review of the RSV Surveillance Pilot Based on the Global Influenza Surveillance and Response System, Bangkok, Thailand 23-25 October 2018 and does not necessarily represent the decisions or policies of WHO

Printed in Switzerland

#### **Background**

Respiratory Syncytial Virus (RSV) is a leading viral cause of acute lower respiratory tract infections in infants and young children. The RSV vaccine development landscape is evolving rapidly with several vaccine candidates and monoclonal antibodies in various stages of clinical development. RSV surveillance has the potential to provide an evidence-base on seasonality, healthcare burden (such as hospitalisations) and risk groups to guide immunization practices once the RSV vaccine becomes available. Current evidence gaps also include RSV associated mortality both in the community and healthcare setting, long term impact of RSV infection on future wheeze and lung function, the economic burden of RSV, cost-effectiveness modelling of prevention strategies, RSV disease burden in pregnancy. The RSV surveillance may provide a platform for special studies to address some of these research questions.

A three-year pilot project on RSV surveillance based on the Global Influenza Surveillance and Response System (GISRS) was initiated globally in 14 countries across all six WHO regions in 2016. The overall aim was to assess the suitability of the influenza surveillance platform for RSV surveillance and identify ways for expansion of existing surveillance criteria to meet the needs for RSV surveillance without negatively affecting influenza surveillance. At the end of the pilot project, a meeting was organised in Bangkok to bring together about 65 international experts from the influenza and RSV communities, participating countries, and other stakeholders, to review and share the final outcomes of the pilot and discuss post-pilot issues and actions including sustainability of the RSV surveillance.

It was noted that when an effective RSV vaccine becomes available there will be a sudden increase in interest in RSV data among policy makers and so data-driven guidance to them will be very valuable. The pilot represents an opportunity to establish a mechanism to generate RSV data for policy purposes at the RSV surveillance pilot sites at low incremental cost. It was agreed that this was a timely opportunity to shape RSV surveillance and establish global guidelines and best practice. It was considered that virologic surveillance would be important to monitor any genetic or antigenic drift, to identify escape mutants, and to understand if genetic changes result in antigenic change and impact on virulence or monoclonal efficacy. The possible impact of any changes on the effectiveness of interventions could then be analysed at the molecular level.

At a time when the RSV research community is mainly focused on product development and research, this RSV surveillance pilot would complement by adding new public health dimensions to the global effort to enrich prevention strategies. Participants supported the approach of building RSV surveillance with available resources to be later scaled up once a vaccine becomes available.

#### The Pilot Phase (phase 1)

The pilot has made very good progress in terms of the primary objective of the pilot. It has confirmed the feasibility of adding RSV surveillance to GISRS with limited additional support. The RSV surveillance platform can produce useful RSV disease morbidity estimates such as proportion of hospitalizations associated with RSV, evaluate the performance of an RSV surveillance case definition, better understand the local RSV seasonality and global circulation of RSV. Extension of surveillance to additional (paediatric) sites has also been a benefit for influenza surveillance. No important adverse impacts, to date, were noted by countries. There was enthusiasm among participating countries for continuing RSV surveillance with similar

level of financial and technical support along with careful monitoring of any potential negative impact on GISRS. Several aspects of the RSV surveillance strategy were discussed including a focus on children less than 2 years with the highest disease burden, the need to define severe clinical outcomes and a clinical severity score to allow a comparison across sites. Monitoring of the implementation of surveillance, referral patterns, contribution of nosocomial RSV infection, to improve data quality and reduce missingness so as to better interpret the findings, was emphasized.

#### Case definition

Despite initial concerns about possible adverse effects on GISRS of adoption of an extended SARI / ILI case definition, as the pilot progressed, all countries reported acceptance of these case definitions without any significant negative impact on influenza surveillance. It was clarified that the SARI case definition for influenza surveillance remained unchanged. Early challenges for physicians to use the extended SARI case definition were resolved through training. More than 21,000 patients were recruited and tested for RSV, of whom 73% were hospital admissions. Overall, 60% of patients tested were less than 5 years (20% less than 6 months, 30% between 6 months to 2 years and 10% between 2 and 5 years age). There was limited recruitment in older age groups. Use of SARI / ILI case definitions would have missed 29% of cases in infants less than 6 months (compared to when using the extended SARI definition).

#### Seasonality

RSV peaked in colder months in temperate regions (duration 5-35 weeks) and in the rainy season in tropical regions. The peaks seemed consistent from year to year in individual countries. There was no difference in season onset across age groups. It was considered essential that further details of the surveillance sites and how they implemented the surveillance (e.g. referral patterns, ICU availability, contribution of nosocomial RSV) be presented to be able to interpret data. It was noted that large sample size and data for more seasons will be required to better understand seasonality. For countries with a large latitudinal spread, sentinel sites would need to be geographically representative of the climactic zones at the sub-national level.

#### Disease burden estimation

RSV surveillance is not expected to produce detailed and robust burden of disease estimates in all or most LMIC. Nonetheless, national policy makers should find useful estimates of RSVassociated hospitalizations in the absence of sophisticated special disease burden estimation studies. A tiered approach was discussed wherein a range of options of morbidity or healthcare burden estimates would be available based on a review of availability of (and effort to generate) denominator-related data along with an explicit understanding of quality, limitations and potential bias of the data. The burden estimates are grouped based on increasing levels of complexity of collecting data from a sentinel surveillance platform. Tier 1 groups burden estimates related to proportions of hospitalization associated with RSV. Tier 2 groups population-based incidence estimates of hospitalization, ICU-based burden, and mortality estimates including case-fatality ratio and proportion of hospital deaths due to RSV. The third tier refers to national extrapolation of population-based hospitalization incidence rates. Countries generally agreed to collect the most basic data (tier 1) required to estimate proportions of hospitalization associated with RSV in the second phase of the surveillance. Countries with additional resources and capacities may opt to use more sophisticated approaches for estimation of RSV disease burden. It was agreed that future directions should make clearer that the RSV surveillance is not trying to encourage all countries towards sophisticated RSV disease burden estimates. Notwithstanding, it was agreed that it was important for some level of burden data feasible from surveillance platform, to be collected in the next phase.

#### Phase 2

The main aims of RSV surveillance pilot phase 1 were focused on establishment of the essential parameters for surveillance. In Phase 2 geographical representation will be increased from the current 1-2 countries per region, focusing on GAVI-eligible countries. The general aim will be to support the future introduction of vaccine into countries. An ICD codes-based methodology for RSV surveillance developed using ICD-codes data from clinics and hospitals in Germany will be tested in other country contexts. Case definitions will be kept the same and will focus on children less than 2 years in phase-2. Case-based data would be retained in Phase 2 to gather these data over several years. The case report form (CRF) will be revised in line with the comments made at this meeting and will aim to include some readily available clinical severity-related data. The feasibility of collecting some specific economic data (direct costs of surveillance) will be explored as costs are likely to vary greatly by setting. Periodic reviews of data quality will be conducted with regular feedback to pilot sites to improve quality.

### RSV detection, typing and sequencing

It was considered that virologic surveillance would be important to monitor genetic or antigenic drift, to identify escape mutants, and to understand if genetic changes result in antigenic change and impact on virulence or monoclonal efficacy. The possible impact of any changes on the effectiveness of interventions could then be analysed at the molecular level. The consensus was that RSV-A/RSV-B typing results and partial or complete RSV genome data would be important. RSV typing will be conducted in all sites by the National Influenza Centres (NIC)s. RSV sequencing will be supported in a few laboratories to bridge the gap of understanding and to help inform future vaccine development. Protocols for RSV sequencing will be developed in Phase 2. This will build on influenza experience with GenBank, GISAID and software tools linking sequence and clinical data. An EQA for RSV typing and for genetic sequencing and detailed guidelines on how laboratories should maintain internal quality control procedures will be developed. WHO will engage with other stakeholders to promote and support international agreement on nomenclature. It was suggested that Phase 2 should aim to show feasibility of generating quality sequence data from the GISRS RSV surveillance platform. A more formal designation as a RSV reference laboratory together with clear terms of reference (including the level of country support envisaged) will be developed to help facilitate getting support from national authorities. It was noted that the project needed a solution for sample storage so that these can be available for future detailed genetic and antigenic characterization studies.

## Way forward

In the second phase, geographical representation will be increased with a focus on GAVIeligible countries. The overall aim will be to support the future introduction of vaccine into countries. The project will develop protocols for RSV typing and sequencing, shipment of virus materials, data sharing and use, and will maintain the high quality of laboratory performance through EQA monitoring.

There was clear support from the Regional Offices and pilot countries for Phase 2 with similar levels of resources being made available. It was considered important to secure funding support from donor agencies to provide additional support to develop laboratory capacity and readiness. Ongoing consideration of future post-pilot sustainability was important given the context that the main financial support was external.

#### <u>Summary</u>

The meeting summarized the outcomes and the lessons learnt from the pilot phase. Key takeaway messages included the feasibility of leveraging the influenza surveillance platform for RSV surveillance without any significant adverse impact; the application of the extended SARI case definition for RSV surveillance; the focus on young children with the highest RSV disease burden; the need to ascertain seasonality patterns and measure simple RSV disease burden estimates such as proportions of hospitalizations due to RSV that would inform policy decisions on vaccine investment and introduction.

Going forward, the meeting concluded to revise the WHO RSV Surveillance strategy for the next phase of surveillance to further focus on children less than 2 years with the highest burden; adopt a tiered approach to disease burden estimation with emphasis on basic estimates of hospital burden of RSV; ascertain RSV circulation by virus type A or B; develop laboratory protocols for RSV typing and schema for sequencing; and expand to countries that are geographically more representative as well as are eligible to receive investment from the Gavi Alliance for RSV vaccine introduction when it becomes available.

#### **Acknowledgements**

This meeting was supported by an award made to the World Health Organization by the Bill & Melinda Gates Foundation (grant no. OPP1127419). We thank Joshua Mott, Centers for Disease Control and Prevention, Bangkok and the WHO Country Office, Thailand for providing local support for the meeting. The WHO acknowledges the contributions by Harish Nair, Chair and all the national and international experts that participated in the meeting. We thank the RSV reference laboratories, the National Influenza Centres, and the National Epidemiology Centres for their support to the WHO RSV Surveillance.

The report was prepared by Harry Campbell and reviewed internally by Siddhivinayak Hirve, Sandra Jackson, Ann Moen and Wenqing Zhang and externally by Harish Nair, Chair of the meeting.

#### Annexes

#### Annex 1: Agenda

## WHO Meeting of Final Review of the RSV Surveillance Pilot based on the Global Influenza Surveillance and Response System (GISRS)

Bangkok, Thailand 23 – 25 October 2018

# **PROVISIONAL AGENDA**

#### Chair: H. Nair Rapporteur: H. Campbell

08:30 – 09:00 Registration   09:00 – 09:20 Opening and welcome Kertesz D, WHO Representative, Thailand   Moen A, Chief, IPR, WHO Karnkawinpong O, Dir General, Dept. of Medical   Sciences, Ministry of Public Health, Thailand Sciences, Ministry of Public Health, Thailand   09:20 – 09:30 Introduction of work Zhang W, Head, GIP, WHO   Disclosure of interest Housekeeping announcement Session co-chair: Chittaganpitch M   09:30 - 09:45 RSV vaccine development - strategic priorities Higgins D   09:45 - 10:00 RSV epidemiology - knowledge gaps Nair H   10:00 - 10:15 WHO RSV surveillance strategy – recap Broor S   10:15 - 10:30 RSV surveillance - progress so far Hirve S   10:30 - 11:40 Coffee Break Hirve S   11:00 - 11:30 Focused plenary discussion Moderator: Gerber S   11:30 - 11:45 Variability in RSV F protein - implications for global surveillance Williams T (Webex) surveillance   surveillance Session Co-chair: Mott J 11:45 - 11:55 Outcome # 1: WHO RSV surveillance strategy Campbell H   11:55 - 12:15 Plenary feedback Moderator - Ziegler T 12:15 - 13:15   11:45 - 11:55	Tuesday, 23 Oc	tober 2018			
Moen A, Chief, IPR, WH∪ Karnkawinpong O, Dir Gerral, Dept. of Medical Sciences, Ministry of Public Health, Thailand Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical Dept. Of Medical Sciences, Ministry of Public Health, Thailand Dept. Of Medical De	08:30-09:00	Registration			
Karnkawinop, Dir Jent, Option of work Disclosure of interest Disclosure of interest Disclosure of interest Disclosure of interest Disclosure of interest Karnkawinop, Cipp, William   Session 1: RSV - Stript the context Session - Sessi	09:00-09:20	Opening and welcome	pening and welcome Kertesz D, WHO Representative, Thailand		
Sciences, Ministry of Public Health, Thailand   09:20 – 09:30 Introduction of work Disclosure of interest Housekeeping announcement Zhang W, Head, GIP, WHO   Session I: RSV - Setting the context Session co-thir: Chittaganpitch M   09:30 - 09:45 RSV vaccine development - strategic priorities Higgins D   09:45 - 10:00 RSV vaccine development - strategic priorities Higgins D   09:45 - 10:00 RSV epidemiology - knowledge gaps Nair H   10:00 - 10:15 WHO RSV surveillance strategy – recap Broor S   10:15 - 10:30 RSV surveillance - progress so far Hirve S   10:30 - 11:40 Coffee Break Uiting T (Webex)   11:30 - 11:45 Variability in RSV F protein - implications for global surveillance Williams T (Webex)   11:45 - 11:55 Outcome # 1: WHO RSV surveillance strategy Campbell H   11:45 - 11:55 Junch break Moderator - Ziegler T   11:45 - 11:55 Junch break Moderator - Ziegler T   12:15 - 13:15 Lunch break Moderator - Ziegler T   13:15 - 13:25 Outcome # 2: External Quality Assurance Baumeister E   13:25 - 13:45 Plenary feedback Moderator - Ziegler T			Moen A, Chief, IPR	, WHO	
09:20 - 09:30Introduction of work Disclosure of interest Disclosure of interest Housekeeping announcementZhang W, Head, GIP, W.Session I: RSV - Sting the contextSession C-Intri Chittaganpitch M09:30 - 09:45RSV vaccine development - strategic prioritiesHiggins D09:45 - 10:00RSV epidemiology - knowledge gapsNair H10:00 - 10:15WHO RSV surveillance strategy - recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakWilliams T (Webex)11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:45 - 11:55Uutcome # 1: WHO RSV surveillance strategyModerator - Ziegler T11:45 - 11:55Uutcome # 1: WHO RSV surveillance strategyModerator - Ziegler T11:45 - 11:55Jutcom # 1: WHO RSV surveillance strategyModerator - Ziegler T11:55 - 12:15Henary feedbackModerator - Ziegler T11:55 - 13:15Lunch breakHirve S13:15 - 13:25Outcom # 2: External Quality AssuranceBaumeister E13:25 - 13:45Henary feedbackModerator - Ziegler T			Karnkawinpong O, I	Dir General, Dept. of Medical	
Disclosure of interest Housekeeping announcementSession co-chair: Chittaganpitch MSession 1: RSV - S+ting the contextSession co-chair: Chittaganpitch M09:30 - 09:45RSV vaccine development - strategic prioritiesHiggins D09:45 - 10:00RSV epidemiology - knowledge gapsNair H10:00 - 10:15WHO RSV surveillance strategy - recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakVariability in RSV F protein - implications for global surveillanceWilliams T (Webex)11:40 - 11:35Variability in RSV F protein - implications for global surveillanceSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakI13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T			Sciences, M	inistry of Public Health, Thailand	
Housekeeping announcement   Session I: RSV -> Ling the context Session I: RSV vaccine development - strategic priorities Higgins D   09:30 - 09:45 RSV vaccine development - strategic priorities Higgins D   09:45 - 10:00 RSV epidemiology - knowledge gaps Nair H   10:00 - 10:15 WHO RSV surveillance strategy – recap Broor S   10:15 - 10:30 RSV surveillance - progress so far Hirve S   Moderator: Gerber S   10:00 - 11:30 Focused plenary discussion Moderator: Gerber S   11:00 - 11:30 Focused plenary discussion Moderator: Gerber S   11:30 - 11:45 Variability in RSV F protein - implications for global arrow Williams T (Webex)   11:45 - 11:55 Outcome # 1: WHO RSV surveillance strategy Campbell H   11:45 - 11:55 Plenary feedback Moderator - Ziegler T   11:45 - 11:55 Plenary feedback Moderator - Ziegler T   11:55 - 13:15 Outcome # 2: External Quality Assurance Baumeister E   13:25 - 13:45 Henry feedback Moderator - Ziegler T	09:20-09:30	Introduction of work	Zhang W, Head, GII	P, WHO	
Session I: RSV - Setting the contextSession co-chair: Chittaganpitch M09:30 - 09:45RSV vaccine development - strategic prioritiesHiggins D09:45 - 10:00RSV epidemiology - knowledge gapsNair H10:00 - 10:15WHO RSV surveillance strategy - recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakItive S11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakItiven S13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T		Disclosure of interest			
09:30 - 09:45RSV vaccine development - strategic prioritiesHiggins D09:45 - 10:00RSV epidemiology - knowledge gapsNair H10:00 - 10:15WHO RSV surveillance strategy - recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee Break		Housekeeping announcement			
09:45 - 10:00RSV epidemiology - knowledge gapsNair H10:00 - 10:15WHO RSV surveillance strategy - recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakIII:00 - 11:3011:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session LI: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakIII:45 - 11:5513:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	Session I: RSV -	Setting the context	Sessi	ion co-chair: Chittaganpitch M	
10:00 - 10:15WHO RSV surveillance strategy – recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakModerator: Gerber S11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakI13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	09:30 - 09:45	RSV vaccine development - strategic	priorities	Higgins D	
10:00 - 10:15WHO RSV surveillance strategy – recapBroor S10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakModerator: Gerber S11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakI13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T					
10:15 - 10:30RSV surveillance - progress so farHirve S10:30 - 11:00Coffee BreakModerator: Gerber S11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession II: RSV surveillance - Pilot OutcomesCampbell H11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakIII: 13:15 - 13:2513:25 - 13:45Plenary feedbackModerator - Ziegler T	09:45 - 10:00	RSV epidemiology - knowledge gaps		Nair H	
10:30 - 11:00Coffee Break11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakIII:45 - 13:2513:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	10:00 - 10:15	WHO RSV surveillance strategy – recap		Broor S	
11:00 - 11:30Focused plenary discussionModerator: Gerber S11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakIII:45 - 13:2513:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	10:15 - 10:30	RSV surveillance - progress so far		Hirve S	
11:30 - 11:45Variability in RSV F protein - implications for global surveillanceWilliams T (Webex)Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakSurveillance13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	10:30 - 11:00	Coffee Break			
In The Colspan="2"surveillancesurveillanceSession II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakExternal Quality AssuranceBaumeister E13:15 - 13:25Outcome # 2: External Quality AssuranceModerator - Ziegler T	11:00 - 11:30	Focused plenary discussion		Moderator: Gerber S	
Session II: RSV surveillance - Pilot OutcomesSession co-chair: Mott J11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler TI2:15 - I3:15Lunch breakSumeister E13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	11:30 - 11:45	Variability in RSV F protein - implications for global		Williams T (Webex)	
11:45 - 11:55Outcome # 1: WHO RSV surveillance strategyCampbell H11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch breakIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII		surveillance			
11:55 - 12:15Plenary feedbackModerator - Ziegler T12:15 - 13:15Lunch break13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	Session II: RSV	surveillance - Pilot Outcomes		Session co-chair: Mott J	
12:15 - 13:15Lunch break13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	11:45 - 11:55	Outcome # 1: WHO RSV surveillance	e strategy	Campbell H	
13:15 - 13:25Outcome # 2: External Quality AssuranceBaumeister E13:25 - 13:45Plenary feedbackModerator - Ziegler T	11:55 - 12:15	Plenary feedback		Moderator - Ziegler T	
13:25 - 13:45Plenary feedbackModerator - Ziegler T	12:15 - 13:15	Lunch break			
	13:15 - 13:25	Outcome # 2: External Quality Assura	ance	Baumeister E	
13:45 - 14:00Outcome # 3: Case definitionCrawford N	13:25 - 13:45	Plenary feedback		Moderator - Ziegler T	
	13:45 - 14:00	Outcome # 3: Case definition		Crawford N	

14:00 - 14:15	Outcome # 4: RSV seasonality	Chadha M
14:15 - 14:30	Outcome # 5: RSV disease burden	Moyes J
14:30 - 15:00	Coffee break	
15:00 - 17:30	WG - case definition	Moderator: Broberg E
	WG - seasonality	Moderator: Ziegler T
	WG – burden	Moderator: Pebody R

19.00 – 21.00 Cocktail Reception

Wednesday, 24 October 2018 09:00 - 09:10Recap of Day 1 Nair H / Campbell H 09:10 - 10:00 Feed-forward -WG (case definition) Broberg E WG (seasonality) Ziegler T WG (burden) Pebody R 10:00 - 10:15 Outcome # 6: Using ICD-10 based data for RSV surveillance Cai W Outcome # 7: Risk factors for severe RSV disease based on ICD 10:15 - 10:30 Cai W codes Coffee break 10:30 - 11:00 11:00 - 11:15 Moderator – Buda S Plenary discussion: Limitations and challenges in use of ICD codes for RSV surveillance 11:15 - 11:45 Panel discussion: Moderator: Gerber S RSV surveillance outcomes - caveats and their implications on Panelist: the outcomes Baumeister E; Bont L; Pebody R; Nair H 11:45 - 12:15 Plenary discussion - what could have been done differently? Moderator – Fasce R

# 预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5\_25539